MedPath

Biohaven Pharmaceuticals, Inc.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
$3.9B
Website

Clinical Trials

33

Active:19
Completed:7

Trial Phases

3 Phases

Phase 1:16
Phase 2:3
Phase 3:11

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials

Phase 1
16 (53.3%)
Phase 3
11 (36.7%)
Phase 2
3 (10.0%)

Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)

Conditions
SCA
Spinocerebellar Ataxias
First Posted Date
2023-09-13
Last Posted Date
2024-11-05
Lead Sponsor
Biohaven Pharmaceuticals, Inc.
Registration Number
NCT06034886

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

Phase 3
Active, not recruiting
Conditions
SMA
Neuromuscular Diseases
Spinal Muscular Atrophy
Interventions
First Posted Date
2022-04-20
Last Posted Date
2025-06-18
Lead Sponsor
Biohaven Pharmaceuticals, Inc.
Target Recruit Count
269
Registration Number
NCT05337553
Locations
🇺🇸

Phoenix Children's, Phoenix, Arizona, United States

🇺🇸

UCSD & Rady Children's, La Jolla, California, United States

🇺🇸

Children's Hospital of Los Angeles, Los Angeles, California, United States

and more 50 locations

Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)

Conditions
Multiple System Atrophy (MSA)
First Posted Date
2021-10-20
Last Posted Date
2022-10-06
Lead Sponsor
Biohaven Pharmaceuticals, Inc.
Registration Number
NCT05086094
Locations
🇺🇸

PPD, Morrisville, North Carolina, United States

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

Phase 3
Conditions
Obsessive Compulsive Disorder
Interventions
First Posted Date
2021-01-14
Last Posted Date
2025-01-17
Lead Sponsor
Biohaven Pharmaceuticals, Inc.
Target Recruit Count
1200
Registration Number
NCT04708834
Locations
🇺🇸

Metropolitan Neuro Behavioral Institute, Chandler, Arizona, United States

🇺🇸

Alea Research, Phoenix, Arizona, United States

🇺🇸

NoeisisPharma, LLC, Phoenix, Arizona, United States

and more 172 locations

Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

Phase 3
Active, not recruiting
Conditions
Obsessive-Compulsive Disorder
Interventions
Drug: Placebo
First Posted Date
2021-01-05
Last Posted Date
2025-01-14
Lead Sponsor
Biohaven Pharmaceuticals, Inc.
Target Recruit Count
700
Registration Number
NCT04693351
Locations
🇺🇸

Alea Research, Phoenix, Arizona, United States

🇺🇸

ProScience Research Group, Culver City, California, United States

🇺🇸

Kaizen Brain Center, La Jolla, California, United States

and more 85 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

Biohaven's Obesity Program Gains Analyst Confidence Despite SMA Trial Setback

• Baird maintains an Outperform rating for Biohaven, encouraged by positive body composition changes observed in a Phase 3 SMA trial, signaling potential in the upcoming Phase 2 obesity trial. • Biohaven's management expresses strong optimism for their degrader platform, anticipating key results soon, which contributes to the positive outlook despite the recent Phase 3 SMA trial failure. • Despite a setback in the Phase 3 trial of taldefgrobep for spinal muscular atrophy (SMA), analysts remain confident in Biohaven's broader R&D portfolio, particularly its obesity program.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.